Disparities in breast, lung, and cervical cancer trials worldwide
| dc.creator | Ramya Ramaswami | |
| dc.creator | Eduardo Paulino | |
| dc.creator | Adriana Barrichello | |
| dc.creator | Angélica Nogueira Rodrigues | |
| dc.creator | Alexandra Bukowski | |
| dc.creator | Jessica St. Louis | |
| dc.creator | Paul e. Goss | |
| dc.date.accessioned | 2023-08-11T20:32:11Z | |
| dc.date.accessioned | 2025-09-09T01:16:41Z | |
| dc.date.available | 2023-08-11T20:32:11Z | |
| dc.date.issued | 2018 | |
| dc.format.mimetype | ||
| dc.identifier.doi | 10.1200/JGO.17.00226 | |
| dc.identifier.issn | 2378-9506 | |
| dc.identifier.uri | https://hdl.handle.net/1843/57767 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Journal of Global Oncology | |
| dc.rights | Acesso Aberto | |
| dc.subject | Neoplasias da Mama | |
| dc.subject | Neoplasias Pulmonares | |
| dc.subject | Neoplasias do Colo do Útero | |
| dc.subject.other | Breast Cancer | |
| dc.subject.other | Cervical Cancer | |
| dc.subject.other | Lung Cancer | |
| dc.title | Disparities in breast, lung, and cervical cancer trials worldwide | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 11 | |
| local.citation.issue | 4 | |
| local.citation.spage | 1 | |
| local.citation.volume | 1 | |
| local.description.resumo | Purpose As cancer burden has risen worldwide, physicians, patients, and their advocates have become aware that the clinical cancer trial research paradigm is not ubiquitous. Furthermore, the number and characteristics of trials that are registered in low- and middle-income countries (LMICs) compared with that in high-income countries (HICs) are unknown.Methods We collected retrospective data on trials for breast, lung, and cervical cancer registered in ClinicalTrials.gov or with the WHO International Clinical Trial Registry Platform between 2010 and 2017. The data were then classified as trials within LMICs or HICs using definitions from the World Bank.Results Included in these analyses were 6,710 trials, of which 3,164 (47%) were breast cancer trials, 3,283 (49%) were lung cancer trials, and 263 (4%) were cervical cancer trials. There were 1,951 (29%) trials from LMICs and 4,759 (71%) trials from HICs (P < .001). Although the proportion of phase III trials in HICs versus LMICs was similar (18% v 17%; P = .66), the number of phase I trials in LMICs was significantly lower than that of HICs (20% v 2%; P < .001). For several LMICs with the highest mortality-to-incidence ratios for breast, lung, or cervical cancer, there were no cancer trials registered in the registration data bases searched for this work.Conclusion There are differences in access to cancer clinical trials in LMICs compared with HICs. Several factors, such as excessive cost and a lack of infrastructure and expertise, may explain these differences. | |
| local.publisher.country | Brasil | |
| local.publisher.department | MED - DEPARTAMENTO DE CLÍNICA MÉDICA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://ascopubs.org/doi/10.1200/JGO.17.00226?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed |